Oncological Disease
 European School of Haematology    Multinational Association of Supportive Care in Cancer    The European Organisation for the Research and Treatment of Cancer    European Society of Gynaecological Oncology 
Oncological Disease » Brain Tumor »
Tuesday, 13 May, 2008



Brain Tumor

Hot Topic
Customized Virus Kills Brain Tumor Stem Cells That Drive Lethal Cancer
12 September 2007
A tailored virus destroys brain tumor stem cells that resist other therapies and cause lethal re-growth of cancer after surgery, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Sept. 18 edition of the Journal of the National Cancer Institute.

Further Reading
Other Articles from Touch


A selection of must-have articles

Glioblastoma
New Approach to Combat Glioblastoma Shows Promise in Preclinical Studies
Glioblastoma multiforme (GBM) develops in the tissue of the brain and grows quickly, often becoming very large before a person experiences symptoms and is diagnosed.

Glioblastoma
Glioblastoma Multiforme—Treating a Deadly Tumor with Both Strands of RNA
Gliomas are the most common primary tumors of the brain, with an incidence of about 25,000 new cases per year in the United States. At least half of all gliomas exhibit aggressive, malignant behavior.

Poly IC in cells
EGF Receptor-Targeted Synthetic Double-Stranded RNA Eliminates Glioblastoma, Breast Cancer, and Adenocarcinoma Tumors in Mice
A novel strategy to selectively induce the death of glioblastoma cells and other cancer cells that over-express the EGF receptor.

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) Investigational study to assess the overall response (OR) rate (CR + PR) of Imatinib mesylate and Hydroxyurea (Hydroxycarbamide) combination therapy on patients with recurrent glioblastoma multiforme (brain tumors). This study will also evaluate duration of tumor response (as per MacDonald criteria), clinical benefit, progression free survival rate at 6 and 12 month for the combined treatment and the survival rate at 12 and 24 months.

Safety and Pharmacokinetics Study of Erlotinib (Tarceva) to Treat Patients With Recurrent Glioblastoma Multiforme
We are proposing a novel dose escalation scheme of erlotinib, administered at 3-day intervals to patients with glioblastoma multiforme (GBM), a type of brain tumor. Our hypothesis is that a higher dose administered at 3-day intervals will achieve a more effective and less toxic alternative to daily dosing. In addition, we will examine the metabolism of erlotinib by specific liver enzymes and determine how well erlotinib penetrates the blood-brain-barrier in order to reach target site(s).
Editor's Choice

Whole brain radiotherapy for brain metastases from breast cancer: estimation of survival using two stratification systems

Viani and colleagues have examined the prognostic factors evaluated for overall survival rate for patients with brain metastases from breast cancer, stratified by RPA class and brain metastases score (BS-BM).

The data suggests that patients with BM from breast cancer classified as RPA class I may be effectively treated with local resection followed by WBRT, mainly in those patients with single BM, higher KPS and cranial extra disease controlled. RPA class was shown to be the most reliable indicators of survival.

Symposium Spotlight

2007 Symposium on Gliomas and Secondary Brain Tumors - September 29th



SYMPOSIUM DESCRIPTION & PURPOSE
The 2007 Symposium on Gliomas and Secondary Brain Tumors is designed to provide a comprehensive overview of the biology, screening, and diagnosis of gliomas as well as the use of chemotherapy and targeted agents in their management. The symposium will address the pathology and molecular classification of malignant gliomas and its impact on current treatment strategies and trial design. Standards on the use of surgery, radiation therapy, and chemotherapy will be presented as well as the goals and direction of future trials. Novel imaging techniques and new delivery methods for radiation therapy will be discussed. The utilization of signal transduction inhibitors and other targeted agents will also be reviewed, including recommendations on their integration into current clinical management strategies. Participants will also be updated on current approaches to the treatment of patients with low-grade gliomas and secondary brain tumors. This symposium will include didactic lectures presented by national opinion leaders who will discuss all facets of research in this area, interactive discussions, and question-and-answer sessions that will allow community oncologists to review emerging data in this field and interact with the faculty.

Guidelines Watch
A round up of the latest Clinical Guidelines from the National Guideline Clearinghouse (NGC)

Single brain metastasis
American College of Radiology - Medical Specialty Society. 1999 (revised 2006). 7 pages. NGC:005132

Pre-irradiation evaluation and management of brain metastases
American College of Radiology - Medical Specialty Society. 1999 (revised 2005). 7 pages. NGC:004635


Upcoming Events
Cancer Epigenetics
28 -  31 May 2008
Boston Park Plaza Hotel, Boston, USA
2008 ASCO Annual Meeting
30 May -  03 Jun 2008
McCormick Place, Chicago, USA
ASCO Annual Meeting
30 May -  03 Jun 2008
McCormick Place, Chicago, USA


  Copyright Touch Briefings 2005 - 2008    Terms & Conditions | Privacy Statement|

Articles : a b c d e f g h i j k l m n o p q r s t u v w x y z
Companies : a b c d e f g h i j k l m n o p q r s t u v w x y z
Events : a b c d e f g h i j k l m n o p q r s t u v w x y z
Keywords : a b c d e f g h i j k l m n o p q r s t u v w x y z

Specialities :

Brain Tumor Breast Cancer Cervical Cancer Colorectal Cancer Endometrial Cancer Gastrointestinal Cancer Genitourinary Cancer Leukemia Lung Cancer Ovarian Cancer

Other Touch Group sites:   

Cardiology - Endocrine Disease - Oncological Disease - Gastroenterology - Respiratory Disease